58O Safety interim analysis (SIA) of the phase III postneoadjuvant SASCIA study evaluating sacituzumab govitecan (SG) in patients with primary HER2-negative breast cancer (BC) at high relapse risk after neoadjuvant treatment

Authors :: F. Marmé
C. Hanusch
J. Furlanetto
P. Morris
T. Link
C. Denkert
P.A. Fasching
C. Jackisch
S. Antolín
C. Solbach
P. Aftimos
J. Huober
M. Untch
M. Balic
M. Reinisch
J-U. Blohmer
A. Gonçalves
J. Rey
T. Büchele
S. Loibl
Source :: Annals of Oncology. 33:S148-S149
Publication Year :: 2022
Publisher :: Elsevier BV, 2022.

Tools